Equities research analysts predict that Cancer Genetics Inc (NASDAQ:CGIX) will announce $9.45 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Cancer Genetics’ earnings, with the lowest sales estimate coming in at $9.00 million and the highest estimate coming in at $9.90 million. Cancer Genetics reported sales of $7.23 million in the same quarter last year, which suggests a positive year-over-year growth rate of 30.7%. The firm is expected to report its next quarterly earnings results on Thursday, March 22nd.

According to Zacks, analysts expect that Cancer Genetics will report full year sales of $9.45 million for the current financial year, with estimates ranging from $30.17 million to $31.79 million. For the next financial year, analysts expect that the company will post sales of $43.10 million per share, with estimates ranging from $37.70 million to $48.49 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Cancer Genetics.

Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Thursday, November 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). Cancer Genetics had a negative net margin of 54.65% and a negative return on equity of 46.21%.

A number of research firms recently weighed in on CGIX. HC Wainwright set a $6.00 price target on shares of Cancer Genetics and gave the stock a “buy” rating in a research report on Tuesday. Maxim Group began coverage on shares of Cancer Genetics in a research report on Thursday, December 7th. They set a “buy” rating and a $6.00 price target on the stock. ValuEngine lowered shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $5.56.

Cancer Genetics (NASDAQ:CGIX) opened at $2.00 on Thursday. The firm has a market cap of $56.79, a PE ratio of -2.06 and a beta of 1.11. Cancer Genetics has a 52-week low of $1.65 and a 52-week high of $5.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01.

In other Cancer Genetics news, Director John Pappajohn purchased 150,000 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were purchased at an average cost of $1.86 per share, for a total transaction of $279,000.00. Following the completion of the transaction, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 21.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of CGIX. Northern Trust Corp boosted its position in Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after acquiring an additional 12,168 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Cancer Genetics by 61.9% in the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after purchasing an additional 197,619 shares during the last quarter. Finally, Granahan Investment Management Inc. MA boosted its holdings in Cancer Genetics by 26.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after purchasing an additional 49,371 shares during the last quarter. Hedge funds and other institutional investors own 11.13% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “$9.45 Million in Sales Expected for Cancer Genetics Inc (CGIX) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/18/9-45-million-in-sales-expected-for-cancer-genetics-inc-cgix-this-quarter-3.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Get a free copy of the Zacks research report on Cancer Genetics (CGIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.